Cyron Therapeutics has secured $40 million in Series C funding led by global healthcare investment firm OrbiMed. Existing investors SoftBank Ventures and Kakao Ventures participated alongside new investors in this round.
The funding will be used for global clinical expansion of key pipelines, recruitment of new R&D personnel, and establishment of a U.S. subsidiary. The company plans to focus on preparations for U.S. Phase 2 clinical trials scheduled for the first half of next year.
Jonathan Silverstein, Partner at OrbiMed, stated, "Cyron's innovative technology and strong pipeline have sufficient competitiveness in the global market. We will actively support them through to NASDAQ listing."
With this investment, Cyron Therapeutics' cumulative funding exceeds $80 million, with a valuation of $400 million, positioning the company on the verge of unicorn status.